SETI Hub Wiki - User contributions [en]

Capecitabine: An Oral Fluoropyrimidine In Cancer Therapy

2026-06-17T16:13:50Z

SangWatriama: Created page with " Capecitabine is an oral prodrug of the antimetabolite 5-fluorouracil (5-FU) that is widely used in the treatment of several solid tumors, particularly colorectal and breast cancers. Developed to improve the therapeutic index and convenience of intravenous 5-FU, capecitabine undergoes a multistep enzymatic activation process preferentially in tumor tissues, thereby increasing local drug concentration while reducing systemic toxicity. This report provides a concise ove..."

Capecitabine is an oral prodrug of the antimetabolite 5-fluorouracil (5-FU) that is widely used in the treatment of several solid tumors, particularly colorectal and breast cancers. Developed to improve the therapeutic index and convenience of intravenous 5-FU, capecitabine undergoes a multistep enzymatic activation process preferentially in tumor tissues, thereby increasing local drug concentration while reducing systemic toxicity. This report provides a concise overview of capecitabine, covering its pharmacology, clinical indications, adverse effects, and practical considerations. Mechanism of Action and Metabolism Capecitabine is a rationally designed prodrug that is converted to 5-FU through a three-step enzymatic cascade. Following oral administration, it is absorbed intact from the gastrointestinal tract. In the liver, carboxylesterase hydrolyzes capecitabine to 5’-deoxy-5-fluorocytidine (5’-DFCR). Then, cytidine deaminase, primarily in the liver and tumor tissues, converts 5’-DFCR to 5’-deoxy-5-fluorouridine (5’-DFUR). Finally, thymidine phosphorylase (TP) [https://De.bab.la/woerterbuch/englisch-deutsch/cleaves cleaves] 5’-DFUR to release active 5-FU. TP is significantly upregulated in many tumors compared to normal tissues, providing a degree of tumor selectivity. Within the cell, 5-FU is further metabolized to cytotoxic nucleotides that inhibit thymidylate synthase (TS) and incorporate into RNA and DNA, leading to disrupted DNA synthesis and cell death. The preferential activation in tumors enhances local efficacy and reduces exposure of healthy tissues. Pharmacokinetics Capecitabine is rapidly and extensively absorbed after oral intake, with peak plasma concentrations achieved within 1.5 to 2 hours. Food reduces both the rate and extent of absorption, so it is typically administered within 30 minutes after a meal to minimize variability. The drug is extensively metabolized in the liver, and its metabolites are excreted mainly renally. The elimination half-life of capecitabine and its metabolites is short (0.5–1.5 hours), but the active 5-FU is rapidly cleared. The pharmacokinetics are nonlinear at higher doses. Because of renal clearance, dose adjustment is required in patients with moderate renal impairment (creatinine clearance 30–50 mL/min). A hematopoietic and gastrointestinal toxicity profile is dose-limiting, with hand-foot syndrome (palmar-plantar erythrodysesthesia) being a common and characteristic side effect. Clinical Indications Capecitabine is approved for use in: Colorectal cancer: As adjuvant therapy for stage III (Dukes C) colon cancer after complete resection, and as first-line treatment for metastatic colorectal cancer, often in combination with oxaliplatin (XELOX) or irinotecan (XELIRI) or as a single agent. Breast cancer: In combination with docetaxel for advanced or metastatic disease after failure of prior anthracycline therapy, or as monotherapy in taxane-resistant patients. It is also used in some settings for HER2-positive breast cancer with trastuzumab. Gastric and esophageal cancers: Often in combination with platinum agents (e.g., cisplatin) or as part of perioperative regimens. Pancreatic cancer: In combination with gemcitabine or as part of chemoradiation protocols. Additionally, off-label uses include head and neck, bladder, and other gastrointestinal malignancies. Dosing Regimens The typical dose for intermittent monotherapy is 1250 mg/m² twice daily for 14 days followed by a 7-day rest (21-day cycle). In combination therapy, lower doses are used, e.g., 1000 mg/m² twice daily with docetaxel or 850–1000 mg/m² twice daily with oxaliplatin. Continuous dosing schedules exist but are less common. Dose modifications are based on toxicity grade, with guidelines provided for managing hand-foot syndrome, diarrhea, stomatitis, and myelosuppression. Adverse Effects The most common adverse effects of capecitabine include: Gastrointestinal: diarrhea, nausea, vomiting, stomatitis, abdominal pain. Diarrhea can be severe and requires prompt management with loperamide and hydration. Dermatological: hand-foot syndrome (palmar-plantar erythrodysesthesia) presents as symmetrical, painful erythema, swelling, and desquamation of palms and soles. Incidence correlates with cumulative dose and schedule; management includes dose reduction, treatment breaks, and symptomatic measures such as emollients, steroids, 200mg ([http://laliqua.es/seroquel/ http://laliqua.es/seroquel/]) and avoidance of heat/friction. Hematologic: neutropenia, anemia, thrombocytopenia (less common than with IV 5-FU). Hepatic: transient elevation of transaminases and bilirubin. Metabolic: hypercalcemia, particularly in patients with bone metastases. Cardiac: rare but serious; symptoms mimicking angina or myocardial infarction can occur, likely due to coronary vasospasm. Patients with prior coronary artery disease are at increased risk. Ocular: lacrimation, conjunctivitis. Less common effects include fatigue, anorexia, headache, and neuropathy. Drug Interactions Capecitabine interacts with warfarin and other coumarin anticoagulants, potentiating their effect; frequent INR monitoring is essential during and after treatment. It also increases the toxicity of phenytoin. The antacid aluminum hydroxide/magnesium hydroxide can reduce absorption; separation by at least 2 hours is recommended. Leucovorin (folinic acid) potentiates 5-FU activity and toxicity when given with capecitabine, and this combination must be used with caution. Inhibitors and inducers of CYP2C9 and dihydropyrimidine dehydrogenase (DPD) may affect metabolism, though clinically significant interactions are limited. Contraindications and Precautions Capecitabine is contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency, a genetic disorder that leads to severe and potentially fatal toxicity from 5-FU. Screening for DPD deficiency (via genotyping or phenotype testing) is recommended in some regions before starting treatment, though not universal. Other contraindications include severe renal impairment (creatinine clearance Monitoring and Supportive Care Before each cycle, complete blood count, renal and liver function tests are recommended. Patients should be educated about early signs of hand-foot syndrome (e.g., tingling, burning) and diarrhea. Loperamide is prescribed for diarrhea, and topical corticosteroids and emollients for hand-foot syndrome. Dose adjustments follow standard algorithms based on toxicity grade. For patients who develop severe or recurrent toxicity, testing for DPD deficiency is warranted, and alternative therapies may be considered. Conclusion Capecitabine is an effective and convenient oral alternative to intravenous 5-FU, offering similar efficacy in many settings with a distinct toxicity profile that includes hand-foot syndrome and diarrhea. Its tumor-selective activation provides a therapeutic advantage, though careful patient selection, dose adjustment, and vigilant management of adverse events are essential. [https://www.Buzzfeed.com/search?q=Ongoing Ongoing] research continues to explore combinations and scheduling to optimize outcomes. Overall, capecitabine remains a cornerstone of modern chemotherapy for gastrointestinal and breast cancers.

Mebendazole: A Comprehensive Overview Of An Anthelmintic Agent

2026-06-17T15:14:29Z

SangWatriama: Created page with " Mebendazole is a broad-spectrum anthelmintic medication primarily used to treat parasitic worm infections. First synthesized in the 1970s, it belongs to the benzimidazole class of drugs, which also includes albendazole and thiabendazole. Mebendazole is widely recognized for its effectiveness against common intestinal nematodes such as pinworms (Enterobius vermicularis), roundworms (Ascaris lumbricoides), whipworms (Trichuris trichiura), and hookworms (Ancylostoma duo..."

Mebendazole is a broad-spectrum anthelmintic medication primarily used to treat parasitic worm infections. First synthesized in the 1970s, it belongs to the benzimidazole class of drugs, which also includes albendazole and thiabendazole. Mebendazole is widely recognized for its effectiveness against common intestinal nematodes such as pinworms (Enterobius vermicularis), roundworms (Ascaris lumbricoides), whipworms (Trichuris trichiura), and hookworms (Ancylostoma duodenale and Necator americanus). Its mechanism of action, pharmacokinetics, clinical applications, safety profile, and emerging research make it a cornerstone in global public health efforts to control soil-transmitted helminthiases. Mechanism of Action Mebendazole exerts its anthelmintic effects by selectively binding to β-tubulin in parasitic cells, [https://search.usa.gov/search?affiliate=usagov&query=inhibiting%20microtubule inhibiting microtubule] polymerization. This disrupts glucose uptake and energy metabolism, leading to the depletion of intracellular glycogen stores and ultimately causing immobilization and death of the worm. Because mammalian tubulin binds mebendazole with much lower affinity, the drug has a favorable therapeutic index. The slow onset of action typically results in worm expulsion within one to three days after administration. Pharmacokinetics Mebendazole is administered orally and has poor aqueous solubility, which limits its absorption. Its bioavailability is increased when taken with fatty foods. The drug undergoes extensive first-pass metabolism in the liver, primarily via cytochrome P450 enzymes, and is converted to inactive metabolites that are excreted in bile and urine. The plasma half-life is approximately three to six hours. For intestinal infections, systemic absorption is minimal, but higher doses used in hydatid disease achieve therapeutic serum levels. Clinical Uses The primary indication for mebendazole is the treatment of single or mixed intestinal helminth infections. The standard dose for most infections is 100 mg twice daily for three days, or a single 500 mg dose for enterobiasis. It is also used in the management of trichinosis, though alternatives may be preferred. For cystic hydatid disease caused by Echinococcus granulosus, prolonged high-dose therapy (e.g., 400–600 mg three times daily for [https://lafarolashop.com/images/products/cialis-professional.webp Help & FAQ] one to six months) may be given, often adjunct to surgical or percutaneous intervention. Mebendazole is included on the World Health Organization’s Model List of Essential Medicines and is frequently employed in mass drug administration programs in endemic regions. Side Effects and Contraindications Mebendazole is generally well tolerated. Adverse effects are uncommon and usually mild, including abdominal pain, diarrhea, nausea, vomiting, headache, and rash. Rarely, transient elevation of liver enzymes occurs. High-dose, prolonged treatment has been associated with hepatitis, alopecia, bone marrow suppression, and agranulocytosis. Contraindications include hypersensitivity to benzimidazoles, pregnancy (particularly first trimester) due to embryotoxicity in animal studies, and severe hepatic impairment. The drug is not recommended in children under two years of age unless benefit clearly outweighs risk. Drug Interactions Mebendazole may interact with cimetidine, which can increase its plasma levels, and with anticonvulsants (phenytoin, carbamazepine) that may reduce its efficacy through enzyme induction. Co-administration with metronidazole has been associated with Stevens-Johnson syndrome in rare reports. Resistance and Limitations Resistance to mebendazole has been documented in veterinary use and is emerging in human populations, particularly where mass drug administration is widespread. Genetic mutations in β-tubulin can reduce drug binding. Combination therapy with other anthelmintics like ivermectin or albendazole may help delay resistance and improve efficacy against mixed infections. Emerging Research and Repurposing Beyond its anthelmintic role, mebendazole has attracted attention for potential anticancer properties. Preclinical studies and case reports suggest that mebendazole may inhibit microtubule formation in cancer cells, induce apoptosis, reduce angiogenesis, and sensitize tumors to chemotherapeutic agents. In vitro and in vivo activity has been reported against glioblastoma, melanoma, colorectal, lung, and breast cancer lines. However, [https://openclipart.org/search/?query=large-scale%20clinical large-scale clinical] trials are lacking, and its use for this indication remains investigational. Additionally, mebendazole is being studied for neuroprotection in neurodegenerative diseases due to its anti-inflammatory and anti-tubulin effects. Public Health Importance Soil-transmitted helminthiases affect over 1.5 billion people globally, primarily in tropical and subtropical regions with poor sanitation. Mebendazole, along with albendazole, forms the backbone of preventive chemotherapy campaigns targeting school-age children and at-risk populations. Its low cost, single-dose regimen for some infections, and safety profile make it suitable for large-scale distribution. Integrated with water, sanitation, and hygiene (WASH) interventions, such programs have reduced worm burdens and morbidity significantly. Conclusion Mebendazole remains a vital and safe anthelmintic drug with established efficacy against major intestinal nematodes. Its mechanism, pharmacokinetics, and clinical applications are well understood. While resistance and off-label investigations present ongoing challenges, its public health impact is substantial. Future research may broaden its therapeutic utility, but for now, mebendazole continues to serve as an essential tool in combating parasitic infections worldwide.

User:SangWatriama

2026-06-17T15:14:28Z

SangWatriama: Created page with "My name is Wilbur from Pant doing my final year engineering in International Relations. I did my schooling, secured 93% and hope to find someone with same interests in Bird watching. My web blog [https://lafarolashop.com/images/products/cialis-professional.webp Help & FAQ]"

My name is Wilbur from Pant doing my final year engineering in International Relations. I did my schooling, secured 93% and hope to find someone with same interests in Bird watching. My web blog [https://lafarolashop.com/images/products/cialis-professional.webp Help & FAQ]